Effects of Steroid Tapering on Functional Capacity and Neurocognition
Primary Purpose
Glioblastoma Multiforme
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Dexamethasone acetate
Dexamethasone
Sponsored by
About this trial
This is an interventional treatment trial for Glioblastoma Multiforme focused on measuring Randomized, Dexamethasone, Abbreviated, Protracted, Post-operatively
Eligibility Criteria
Inclusion Criteria:
- written informed consent prior to beginning specific protocol procedures,
- histologically proven GBM,
- status-post gross total resection or subtotal resection as indicated by < 2 cm of residual enhancing disease (subjects with unresectable, multifocal, and /or bulky disease will be excluded),
- >18 years and <70 years of age,
- Karnofsky performance index >70%,
- no documented cardiac, neurodegenerative, neuromuscular, or pulmonary disease,
- no contraindications to a 6-minute walk test,
- no contraindications to neurocognitive testing,
- primary treating physician approval, and
- no complications operatively or postoperatively that requires modification of dexamethasone dosing.
- receiving dexamethasone as standard of care.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Protracted (30 days), Dexamethasone
Abbreviated (14 days), dexamethasone
Arm Description
Participants will receive a protracted course (30 days) of dexamethasone after surgery.
Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
Outcomes
Primary Outcome Measures
Functional Capacity (6-minute walk test)
The exercise test is designed to determine how far you can walk in six minutes. This test will take place at the PRT-BTC at Duke University Medical Center and/or Duke University Medical Center inpatient unit on 4100 or 4300 with appropriate medical supervision.
Secondary Outcome Measures
Neurocognitive Function
A computerized neurocognitive test battery called CNS Vital Signs® including verbal memory test, visual memory test, finger tapping test, symbol digit coding, Stroop test, shifting attention test, continuous performance test.
Skeletal Muscle Strength
Isokinetic muscle strength for bilateral grip and bilateral quadriceps.
Patient-Reported Outcomes (PROs)
Assessed by standardized and validated questionnaires including: Depression (Beck Depression Inventory); Quality of Life (Functional Assessment of Cancer Therapy-Brain); Fatigue (Functional Assessment of Cancer Therapy-Fatigue); Cognition (Functional Assessment of Cancer Therapy-Cognition), Symptomalogy Index (Phone Questionnarie/Survery), Computerized Battery from CNS Vital Signs (Medical Outcomes Survey, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Zung Self-Rating Depression Scale).
Body composition
Body-mass index, weight, height, and circumference of the abdomen, hips, and quadriceps.
Biochemical metabolic measurements
Hematocrit (%), albumin (g/mL), fasting blood glucose (mg/dL), fasting insulin (micro IU/mL), insulin like growth facto binding protein 1 (IGFBP-1) (ng/mL), cystatin C (mg/dL), and retinol binding protein 4 (RBP-4).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01169415
Brief Title
Effects of Steroid Tapering on Functional Capacity and Neurocognition
Official Title
Effects of Dexamethasone Tapering Schedules on Functional Capacity and Neurocognition in Patients With Newly Diagnosed Glioblastoma Multiforme
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Withdrawn
Why Stopped
Funding not obtained
Study Start Date
June 2010 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Purpose and Objective:
To compare the effects of either an abbreviated or protracted taper of dexamethasone on functional capacity in newly diagnosed glioblastoma multiforme (GBM) patients.
To compare neurocognitive function in newly diagnosed GBM patients receiving either an abbreviated or protracted taper of dexamethasone.
To compare skeletal muscle strength in newly diagnosed GBM patients receiving either an abbreviated or protracted taper of dexamethasone.
To examine the association between functional capacity and neurocognitive function and patient-reported measures (i.e. quality of life, fatigue, etc.) in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone.
To examine the association between functional capacity and neurocognitive function and body composition measures (body-mass index, etc.) in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone.
To examine the association between functional capacity and neurocognitive function and biochemical metabolic measurements in newly diagnosed GBM patient on either an abbreviated or protracted taper of dexamethasone.
All study endpoints will be assessed at three timepoints as follows: (1) initial assessment after surgery in the hospital, (2) second assessment at initial clinical visit at the Preston Robert Tisch Brain Tumor Center (PRT-BTC) at Duke, approximately 1 week post-operatively, and (3) third assessment at second clinical visit in the PRT-BTC at Duke, approximately 10 weeks post-operatively and after completion of radiotherapy. An additional fourth assessment will be obtained at 4 weeks post-operatively if the subject is undergoing radiotherapy here at Duke.
Detailed Description
The proposed study is a randomized controlled trial. After obtaining written informed consent, all participants will be randomized to either an abbreviated (14 days) or protracted (30 days) course of dexamethasone post-operatively.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioblastoma Multiforme
Keywords
Randomized, Dexamethasone, Abbreviated, Protracted, Post-operatively
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Protracted (30 days), Dexamethasone
Arm Type
Experimental
Arm Description
Participants will receive a protracted course (30 days) of dexamethasone after surgery.
Arm Title
Abbreviated (14 days), dexamethasone
Arm Type
Experimental
Arm Description
Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone acetate
Other Intervention Name(s)
Decadron
Intervention Description
Participants will receive a protracted (30 days) course of dexamethasone after surgery.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Decadron
Intervention Description
Participants will receive a protracted (14 days) course of dexamethasone after surgery.
Primary Outcome Measure Information:
Title
Functional Capacity (6-minute walk test)
Description
The exercise test is designed to determine how far you can walk in six minutes. This test will take place at the PRT-BTC at Duke University Medical Center and/or Duke University Medical Center inpatient unit on 4100 or 4300 with appropriate medical supervision.
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Neurocognitive Function
Description
A computerized neurocognitive test battery called CNS Vital Signs® including verbal memory test, visual memory test, finger tapping test, symbol digit coding, Stroop test, shifting attention test, continuous performance test.
Time Frame
10 weeks
Title
Skeletal Muscle Strength
Description
Isokinetic muscle strength for bilateral grip and bilateral quadriceps.
Time Frame
10 weeks
Title
Patient-Reported Outcomes (PROs)
Description
Assessed by standardized and validated questionnaires including: Depression (Beck Depression Inventory); Quality of Life (Functional Assessment of Cancer Therapy-Brain); Fatigue (Functional Assessment of Cancer Therapy-Fatigue); Cognition (Functional Assessment of Cancer Therapy-Cognition), Symptomalogy Index (Phone Questionnarie/Survery), Computerized Battery from CNS Vital Signs (Medical Outcomes Survey, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Zung Self-Rating Depression Scale).
Time Frame
10 weeks
Title
Body composition
Description
Body-mass index, weight, height, and circumference of the abdomen, hips, and quadriceps.
Time Frame
10 weeks
Title
Biochemical metabolic measurements
Description
Hematocrit (%), albumin (g/mL), fasting blood glucose (mg/dL), fasting insulin (micro IU/mL), insulin like growth facto binding protein 1 (IGFBP-1) (ng/mL), cystatin C (mg/dL), and retinol binding protein 4 (RBP-4).
Time Frame
10 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
written informed consent prior to beginning specific protocol procedures,
histologically proven GBM,
status-post gross total resection or subtotal resection as indicated by < 2 cm of residual enhancing disease (subjects with unresectable, multifocal, and /or bulky disease will be excluded),
>18 years and <70 years of age,
Karnofsky performance index >70%,
no documented cardiac, neurodegenerative, neuromuscular, or pulmonary disease,
no contraindications to a 6-minute walk test,
no contraindications to neurocognitive testing,
primary treating physician approval, and
no complications operatively or postoperatively that requires modification of dexamethasone dosing.
receiving dexamethasone as standard of care.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katherine B Peters, MD, PhD
Organizational Affiliation
Duke Health
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effects of Steroid Tapering on Functional Capacity and Neurocognition
We'll reach out to this number within 24 hrs